A Phase II Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Safety of PG-102(MG12) Compared With Placebo in Subjects With Obesity and in Subjects With Type 2 Diabetes Mellitus (T2DM)
Latest Information Update: 23 Jul 2025
At a glance
- Drugs PG 102 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Progen Pharmaceuticals Limited
Most Recent Events
- 11 Jul 2025 Planned End Date changed from 30 Jun 2025 to 30 Oct 2025.
- 11 Jul 2025 Planned primary completion date changed from 30 Mar 2025 to 30 Oct 2025.
- 11 Jul 2025 Status changed from recruiting to active, no longer recruiting.